Abstract
PICO question
 Does treatment with a non-steroidal anti-inflammatory drug (NSAID) with supplementation of marine-derived omega-3 fatty acids (n-3FAs) compared to the NSAID alone, result in an increased ability to exert force by the osteoarthritic limb(s) of dogs or alleviate other measures of osteoarthritis?
 
 Clinical bottom line
 Category of research question
 Treatment
 The number and type of study designs reviewed
 Two prospective, block-randomised, clinical trials
 Strength of evidence
 None
 Outcomes reported
 Kwananocha et al. (2016) investigated administration of carprofen supplemented with marine-derived n-3 FAs, to carprofen alone, administered over 4 weeks. Vijarnsorn et al. (2019) investigated administration of firocoxib supplemented with n-3FA, to firocoxib alone, for 4 weeks. There were no statistical differences between treatment groups at week 2 and week 4 post-treatment for either study. Both studies also reported orthopaedic assessment score (OAS) based on scoring the extent of patient lameness and pain in the affected joint. There were no statistical changes in OASs between treatment groups at week 2 or week 4 post-treatment for either study
 Conclusion
 There is no evidence that marine-derived n-3 FAs provide additional benefit when used as adjunctive agents with NSAIDs for the treatment of canine osteoarthritis
 
 How to apply this evidence in practice
 The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources.
 Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.
 
Highlights
Sample size: 40 dogs (10 dogs in each group). 49 dogs were initially enrolled, and nine were lost to the study or dismissed
The carprofen and combination treatment groups are relevant to the PICO question
Significant effects of time were found within treatment groups: o When comparing week 6 to week 0, peak vertical force (PVF) values for the carprofen group and combination group were significantly greater with mean ± SD change 2.58 ± 2.48 % body weight (BW) (p = 0.028) and 4.39 ± 2.56 % BW (p = 0.001), respectively. o Comparison of week 8 vs week 0, PVF values for carprofen group and combination group were significantly increased with mean ± SD change 4.23 ± 2.33 % BW (p = 0.001) and 5.36 ± 2.98 % BW (p = 0.001), respectively. o Comparison of week 8 and 6 to week 0, there were no significant changes in PVF values between groups
Summary
Lok Yee Stephanie Wong DVM candidate1* Merran Govendir PhD BVSc MEd(Higher Ed) FHERDSA1. There were no statistical changes in OASs between treatment groups at week 2 or week 4 posttreatment for either study Conclusion There is no evidence that marine-derived n-3 FAs provide additional benefit when used as adjunctive agents with NSAIDs for the treatment of canine osteoarthritis. How to apply this evidence in practice The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources. There are study design limitations in both studies such as inadequate sample size, and other factors such as an insufficient dosage, insufficient duration of dosage and brief study duration
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
